Drug intelligence / Profile preview

cemiplimab + isatuximab

Development stage: Unknown
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of cemiplimab (anti-PD-1 monoclonal antibody) and isatuximab (anti-CD38 monoclonal antibody). This combination was designed to potentially enhance antitumor activity by targeting both immune checkpoint inhibition (PD-1) and CD38-expressing tumor cells. Preclinical data suggested that concurrent treatment with anti-CD38 and anti-PD-1/PD-L1 antibodies could reduce primary tumor growth by reversing T-cell exhaustion.

Brand names: Sarclisa (isatuximab)Libtayo (cemiplimab)
Other names: isatuximab + cemiplimab

Targets

CD38 (Cluster of Differentiation 38)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on cemiplimab + isatuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cemiplimab + isatuximab.

Explore the full profile